Use of bone-modifying agents in myeloma and bone metastases: How recent dosing interval studies have affected our practice

Erica Campagnaro, Melissa A. Reimers, Angel Qin, Ajjai S. Alva, Bryan J. Schneider, Catherine H. Van Poznak

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

The management of bone lesions from advanced solid tumors and multiple myeloma typically includes use of a bone-modifying agent to reduce the risk of skeletal-related events. Recent data demonstrate that when using zoledronic acid to reduce the risk of skeletal-related events in metastatic breast cancer, metastatic prostate cancer, and multiple myeloma, the dosing interval of zoledronic acid may be extended from every 4 weeks to every 12 weeks. The ASCO guidelines on the role of bone-modifying agents in metastatic breast cancer and multiple myeloma address zoledronic acid dosing intervals. Herein, we discuss how new data on dosing of bone-modifying agents influence our clinical practice.

Original languageEnglish
Pages (from-to)457-464
Number of pages8
JournalJournal of Oncology Practice
Volume14
Issue number8
DOIs
StatePublished - Aug 1 2018
Externally publishedYes

Fingerprint Dive into the research topics of 'Use of bone-modifying agents in myeloma and bone metastases: How recent dosing interval studies have affected our practice'. Together they form a unique fingerprint.

Cite this